Company page

Abcellera Biologics Inc.

Abcellera Biologics Inc. (ticker: ABCL) is a public company based in the United States with a market capitalization of approximately $1.69 billion. The company focuses on advancing its innovative technologies in the field of biologics. Abcellera is committed to improving the development of antibody therapies through its proprietary platform.